KOD

Based on Kodiak Sciences Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.

What does Kodiak Sciences do?

Kodiak Sciences is a clinical-stage biopharmaceutical company developing treatments for retinal diseases. Its lead program is an anti-VEGF antibody biopolymer designed to treat wet age-related macular degeneration, diabetic macular edema, and related conditions. The company also has earlier-stage programs targeting dry AMD and inflammatory retinal diseases.

Does KOD pay dividends?

No, Kodiak Sciences does not pay a dividend. As a pre-commercial biotech, the company reinvests all available capital into clinical development and research operations. Dividend payments are not typical for companies at this stage of development.

When does KOD report earnings?

Kodiak Sciences follows a standard quarterly reporting cadence for US-listed companies. Because it has no commercial revenue, reports focus on operating expenses and pipeline progress. Check the company's investor relations page for the most current schedule and recent filings.

Is KOD a good stock to buy?

UQS Score rates KOD as Poor, driven by Weak ratings across Quality, Moat, and Growth pillars, alongside an Elevated Valuation. The Risk pillar is rated Good, which offers some structural reassurance. Whether KOD fits a portfolio depends on an investor's risk tolerance and view on the clinical pipeline. See the full pillar breakdown on UQS Score for a deeper look.

Is KOD overvalued?

UQS Score's Valuation pillar for KOD is rated Elevated, suggesting the current market price may not offer a significant margin of safety relative to the company's pre-revenue, clinical-stage profile. Valuation for biotechs at this stage is heavily tied to pipeline expectations rather than current fundamentals.

How does KOD compare to its competitors?

Compared to peers like Ultragenyx — which has approved commercial products — Kodiak remains earlier in its development journey. Arcus Biosciences and Celldex Therapeutics share the clinical-stage risk profile but operate in different therapeutic areas. UQS Score provides side-by-side pillar comparisons for registered users.

What is KOD's market cap bracket?

Kodiak Sciences is classified as a mid-cap company. This places it in a size range that typically attracts both institutional and retail investor interest, though clinical-stage biotechs at any size carry elevated uncertainty tied to trial outcomes.

Who founded Kodiak Sciences?

Kodiak Sciences was originally incorporated as Oligasis, LLC and later renamed Kodiak Sciences Inc. in September 2015. The company's founding history and leadership background are publicly available through its SEC filings and investor relations materials.

Is KOD a long-term quality indicator?

From a long-term quality perspective, UQS Score currently rates KOD as Poor, with Weak scores across Quality, Moat, and Growth pillars. Long-term value potential depends heavily on clinical trial success. The Good Risk rating is a relative positive, but the overall profile reflects the high-uncertainty nature of pre-commercial biotech investing.

What is the main competitive advantage of Kodiak Sciences?

Kodiak's differentiation centers on its antibody biopolymer platform, which is designed to extend the time between retinal injections — a meaningful quality-of-life improvement for patients if validated. However, UQS Score rates the Moat pillar as Weak, reflecting that this advantage is not yet commercially proven.

What sector does KOD belong to?

Kodiak Sciences operates in the Healthcare sector, specifically within clinical-stage biopharmaceuticals. The company's focus on retinal diseases places it in a specialty ophthalmology niche that includes both large established players and smaller development-stage competitors.

Kodiak Sciences Inc. currently shows below-average quality metrics, suggesting challenges with profitability.

Kodiak Sciences Inc. faces growth headwinds with declining or stagnant revenue trends.

Kodiak Sciences Inc. maintains a reasonable risk profile with manageable debt levels.

Kodiak Sciences Inc. appears expensively valued relative to its fundamentals and growth prospects.

Kodiak Sciences Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for KOD.

The UQS (Unified Quality Score) for Kodiak Sciences Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.

Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.

Moat (25%) assesses Kodiak Sciences Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.

Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.

Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.

Valuation (15%) measures whether Kodiak Sciences Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.

Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.